Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To study the prevalence of hyperuricemia in the Russian regions, depending on the climatic, geographical, socio-demographic characteristics and some cardiometabolic risk factors.

Material and methods. Data from the ESSE-RF study from 10 regions of theRussian Federationare presented. All study participants were examined according to a uniform protocol. Measurements were standardized, biochemical tests were carried out in three Federal centers using the same methodology. The study was approved by independent Ethics committees, and all participants signed informed consent.

Results. The prevalence of hyperuricemia was 16.8% (25.3% in men and 11.3% in women; p<0.0001). Hyperuricemia incidence increases with age, does not depend on education, significantly associates with place of residence, elevated blood pressure, obesity and abdominal obesity, alcohol consumption and diuretics taking. After adjustment for all factors included in the regression analysis, prevalence of hyperuricemia in the Ivanovo Region is 1.4 times higher than this in the reference region (Tyumen), while prevalence of hyperuricemia in the Samara Region and theRepublicofNorth Ossetia-Alaniais 30% and 40 % lower.

Conclusion. Prevalence of hyperuricemia inRussiais defined; regions with the highest and lowest prevalence are identified. Associations of hyperuricemia with some social and demographic characteristics as well as cardiovascular risk factors are revealed.

About the Authors

S. A. Shalnova
State Research Center for Preventive Medicine, Moscow
Russian Federation

A. D. Deev
State Research Center for Preventive Medicine, Moscow
Russian Federation

G. V. Artamonov
Research Institute for Complex Issues of Cardiovascular Diseases under the Siberian Branch of the Russian Academy of Medical Sciences, Kemerovo
Russian Federation

D. V. Duplyakov
Samara Region Clinical Cardiology Hospital
Russian Federation

A. Yu. Efanov
Tyumen State Medical Academy
Russian Federation

Yu. V. Zhernakova
Russian Cardiology Research and Production Complex, Moscow
Russian Federation

A. O. Konradi
Federal Almazov Medical Research Centre, St. Petersburg
Russian Federation

R. A. Libis
Orenburg State Medical Academy
Russian Federation

G. A. Muromtseva
State Research Center for Preventive Medicine, Moscow
Russian Federation

S. V. Nedogoda
8Volgograd State Medical University
Russian Federation

E. V. Oschepkova
Russian Cardiology Research and Production Complex, Moscow
Russian Federation

S. V. Romanchuk
Ivanovo Municipal Cardiology Hospital
Russian Federation

O. P. Rotar
Federal Almazov Medical Research Centre, St. Petersburg
Russian Federation

V. N. Titov
Russian Cardiology Research and Production Complex, Moscow
Russian Federation

Z. A. Toguzova
North Ossetia State Medical Academy, Vladikavkaz
Russian Federation

I. A. Trubacheva
Research Institute for Cardiology under the Siberian Branch of the Russian Academy of Medical Sciences, Tomsk
Russian Federation

G. I. Furmenko
Voronezh State Medical Academy
Russian Federation

E. V. Shlyakhto
Federal Almazov Medical Research Centre, St. Petersburg
Russian Federation

S. A. Boytsov
State Research Center for Preventive Medicine, Moscow
Russian Federation


1. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.J Am Soc Nephrol 2005; 16:355362

2. Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Investig 1977; 60:999-1007

3. Nakagawa T, Mazzali M, Kang DH, et al. Uric acid-a uremic toxin? Blood Purif 2006; 24:67-70.

4. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-80.

5. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18:523-30.

6. Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45:28-33

7. De Leeuw PW, Thijs L, Birkenhäger WH, et al. Prognostic significance of renal function in elderly patients with isolated Systolic hypertension: Results from the Syst-eur trial. J Am Soc Nephrol 2002;13(9):2213-22.

8. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89:12-7.

9. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26.

10. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116: 894-900.

11. Krishnan E, BakerJF, FurstDE, SchumacherHR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54: 2688-96.

12. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA 2000; 283:2404-10.

13. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Intern Med 2004;164: 1546-51.

14. Liese AD, Hense HW, Lowel H, et al. Asso¬ciation of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in theMONICAAugsburg Cohort. Epidemiology 1999;10:391-7

15. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999;131:7-13.

16. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136-43.

17. Soltani Z, Rasheed R, Kapusta DR, Reisin E. Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and CardiovascularDiseases: Is It Time for Reappraisal? Curr Hypertens Rep 2013;15(3):175-81.

18. Abdurhman SAA. Hyperuricemia in Saudi Aradia. Rheumatol Int 2001; 20: 61-4.

19. Chu, NF, Wang DJ, Liou SH, Shieh SM. Relationship between hyperuricemia and other cardiovascular risk factors among adults men in Taivan. Eur J Epidemol 200; 16: 13-7

20. Scientific Organizing Committee of the RF-ESSAY. Epidemiology of cardiovascular disease in different regions of Russia (ESSAY-RF). Rationale and study design. Preventive Medicine 2013; (6): 25-34. Russian (Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайин исследований. Профилактическая Медицина 2013; (6): 25-34).

21. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1973; 1:449-51.

22. Zhu Y, Bhavik J., Pandya BJ, Choi HK. Prevalence of Gout and Hyperuricemia in the US General Population. The National Health and Nutrition Examination Survey 2007-2008. Arthritis & Rheumatism 2011;63(10): 3136-41

23. Sari I, Akar S, Pakoz B, Sisman AR et al.Hyperuricemia and its related factors in urban population. Izmir, Turky. Rheumatol Int 2009; 29: 869-74

24. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.BMC Public Health 2004; 25: 4-9.

25. Liu B, Wang T, Zhao HN et al. The prevalence of hyperuricemia in China: a meta-ayalysis. BMC Oublic health 2011; 11: 832

26. Qiu L, Cheng X, Wu J et al. Prevalence of hyperuricemia and its retated risk factors in healthy aduts from Nothern and Northeastern Chinese provinces. BMC Public health 2013; 13: 664

27. Kazufumi N, Kunitoshi I, Taku I, et al.Hyperuricamia and cardiovascularrik factor clastering in a screened cohot in Okinava, Japan. Hypertens Res 2004; 27: 227-33

28. Ishizaka N, Ishizaka Y, Toda E, et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25:1038-44.

29. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-7

30. Kobalava JD, Tolkacheva VV, Karaulova JL. Uric acid a marker and / or a new risk factor for cardiovascular complications? Russian Journal of Medicine 2002; (10):431-6. Russian (Кобалава Ж.Д., Толкачева В.В., Караулова Ю.Л. Мочевая кислота – маркер и/или новый фактор риска развития сердечно-сосудистых осложнений? Русский Медицинский Журнал 2002;(10):431-6).

31. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 2013; 25:210-6.

32. Osgood K, Krakoff J, Thearle M. Serum Uric Acid Predicts Both Current and Future Components of the Metabolic Syndrome. Metab Syndr Relat Disord 2013; 11(3):157-62.

33. Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013; 99(11):759-66.

34. Jacob S. Patient with beer belly or hypertension. Check for a metabolic syndrome! MMW Fortschr Med 2005; 147:45.

35. Reungjui S et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome.J Am Soc Nephrol 2007; 18:2724-31

36. Titov VN, Boitsov SA, Urazalin SF, et al. Relationship of uric acid in lipid metabolism in individuals with low and medium risk on a scale of SCORE. Dyslipidemia and Atherosclerosis 2013; (2): 31-9. Russian (Титов В.Н., Бойцов С.А., Уразалина С.Ф., и др. Взаимосвязь мочевой кислоты с показателями липидного обмена у лиц с низким и средним риском по шкале SCORE. Атеросклероз и Дислипидемия 2013; (2): 31-9)

37. Nakagawa T,HuH, Zharikov S, et al.A causalrole for uric acid in fructose-induced metabolic syndrome. Am J Physiol Ren Physiol 2006; 290: F625-31.

38. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221-6.

39. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clinical J Am Soc Nephrol 2011; 6:1887-94.

40. Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012; 77:275-82.

41. HoWJ, TsaiWP, Yu KH, et al.Association between endothelial dysfunction and hyperuricaemia. Rheumatology 2010; 49:1929-34.

42. Terawaki H, Nakayama M, Miyazawa E, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clinical and Exp Nephrol 2013;17(4):549-53.

For citation:

Shalnova S.A., Deev A.D., Artamonov G.V., Duplyakov D.V., Efanov A.Y., Zhernakova Y.V., Konradi A.O., Libis R.A., Muromtseva G.A., Nedogoda S.V., Oschepkova E.V., Romanchuk S.V., Rotar O.P., Titov V.N., Toguzova Z.A., Trubacheva I.A., Furmenko G.I., Shlyakhto E.V., Boytsov S.A. HYPERURICEMIA AND ITS CORRELATES IN THE RUSSIAN POPULATION (RESULTS OF ESSE-RF EPIDEMIOLOGICAL STUDY). Rational Pharmacotherapy in Cardiology. 2014;10(2):153-159. (In Russ.)

Views: 558

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)